论文部分内容阅读
目的探讨可手术乳腺癌新辅助化疗的临床疗效。方法将60例可手术乳腺癌随机分为新辅助化疗组和对照组。新辅助化疗组术前作3周期CMF方案(CTX+MTX+5-FU)化疗,术后补充放疗、化疗;对照组除不做术前化疗外,手术及术后其他相同。结果新辅助化疗组临床有效率达68%。两组5年生存率分别为69.8%和56.7%,新辅助化疗组明显高于对照组,其差异有统计学意义(P<0.05)。结论新辅助化疗可提高可手术乳腺癌的临床疗效。
Objective To investigate the clinical efficacy of neoadjuvant chemotherapy for operable breast cancer. Methods Sixty patients with operable breast cancer were randomly divided into neoadjuvant chemotherapy group and control group. The neoadjuvant chemotherapy group was given 3 cycles of CMF regimen (CTX + MTX + 5-FU) chemotherapy before surgery, followed by radiotherapy and chemotherapy. The control group was the same as the other postoperative patients except without preoperative chemotherapy. Results The neoadjuvant chemotherapy group achieved a clinical effective rate of 68%. The 5-year survival rates of the two groups were 69.8% and 56.7% respectively. The neoadjuvant chemotherapy group was significantly higher than that of the control group (P <0.05). Conclusion Neoadjuvant chemotherapy can improve the clinical efficacy of operable breast cancer.